+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tendinopathy - Market Insight, Epidemiology and Market Forecast 2030

  • ID: 5387739
  • Report
  • July 2021
  • Region: Global
  • 152 pages
  • DelveInsight

FEATURED COMPANIES

  • Ipsen
  • MiMedx Group
  • Novartis Pharmaceuticals
  • Orthocell Limited
  • R3 Stem Cell
  • MORE
This ‘Tendinopathy-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Tendinopathy, historical and forecasted epidemiology as well as the Tendinopathy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Tendinopathy market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Tendinopathy market size from 2018 to 2030. The Report also covers current Tendinopathy treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Tendinopathy Disease Understanding and Treatment Algorithm

Tendinopathy Overview

Tendinopathy is an umbrella term for diseases of the tendons - fibrous cords of tissue that hold muscles to bone. Although tendons must be strong and flexible to do their job, they can be injured due to overuse. Tendinopathy broadly refers to three varieties of tendon injury and is often confused with or used synonymously with them. They are as follows:
  • Tendonitis/tendinitis: Inflammation of a tendon, usually due to acute injury caused by overuse or repetitive strain
  • Tendinosis: Chronic tendon injury with little or no inflammation involving micro-tears in the affected tendon. Tendinosis causes long-term pain and is degenerative
  • Paratenonitis: Inflammation of the outer sheath (paratenon) that surrounds certain tendons, such as the Achilles
All of these conditions increase the risk of a more serious tendon tear or rupture
Tendons are “mechanical bridges”; they are strong fibrous structures of pearly color that connect the muscles to the bones, and their primary function is of transforming the force generated by muscle contraction into movement. In addition to this, they can absorb external forces to limit muscle overloads and act as temporary energy storage devices. Due to their proprioceptive properties, tendons are also of primary importance in postural adjustments.

Tendinopathy Diagnosis

The diagnosis of tendinopathy is based on clinical symptoms and patient history of activity-provoked localized tendon pain and stiffness. A detailed clinical examination confirms a patient-reported history of load-related tendon pain and a physical examination (X-ray, MRI scan, Echography, and Ultrasound) is key to diagnosis. For those tendons that are easily palpable, tenderness to palpation is often used to confirm the diagnosis. Palpation is also helpful to differentiate between other structures, such as painful fat pad with patellar tendinopathy or bursitis in Achilles tendinopathy, which might be involved in symptom manifestation. In addition, there might be localized swelling in the area of the tenderness. Screening for risk factors is vital to understand the cause of the injury and design the best treatment plan personalized for each patient. Early detection of tendinopathy is paramount in achieving full recovery, particularly in the sporting population.

Tendinopathy Treatment

The mainstays of initial treatment for tendinopathy are activity modification, relative rest, pain control, rehabilitative exercise, and protection. The patient needs to understand that it may take more than six months for complete symptom resolution. The therapeutic regimens can be divided into passive modalities, including pharmacological treatments, injection therapy, extracorporeal shockwave therapy (ESWT), therapeutic ultrasonography and low-level laser, and active modalities, such as tendon loading exercise, patient education, and load management. In general, the efficacy of treatment should be determined by the reversal of tendinopathy pathology and not just the resolution of the symptomology.

Tendinopathy Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Tendinopathy, Gender-specific Incident Cases of Tendinopathy, Type-specific Incident Cases of Tendinopathy, and Region-specific Incident Cases of Tendinopathy scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Key Findings
  • In 2020, the total incident cases of Tendinopathy were found out to be 29,282,773 in the 7MM.
  • Tendinopathy incidence for the United States has shown an increasing trend. As per the estimates, the United States accounted for 11,920,169 incident cases in 2020 and is estimated to increase in 2030.
  • Among the European 5 countries, France had the highest incident population of Tendinopathy with 4,450,554 cases, followed by the UK and Italy, in 2020. On the other hand, Spain had the lowest incident population of 416,722 in 2020.
  • The Incident Cases of Tendinopathy are on the rise, and it is estimated that Japan accounted for 4,973,588 incident cases in 2020.
Tendinopathy Epidemiology

The epidemiology segment also provides the Tendinopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Tendinopathy Drug Chapters

Tendinopathy Emerging Drugs

Micronized DHACM (MiMedx Group)

Micronized DHACM (AmnioFix) is a dehydrated human amnion/chorion membrane allograft. The product is available in sheet, particulate, and wrap configurations in various sizes to reduce wastage. The product is derived from donated C-sections of live births in the US. The product undergoes active preservation of the extracellular matrix (ECM), regulatory proteins, and removal of blood contaminants via a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized. AmnioFix is SMR2T Technology (Selective Membrane of Reparative and Reconstructive Tissue) which provides a semi-permeable protective barrier that supports the healing cascade. The product protects the wound bed to aid in developing granulation tissue and provides a human biocompatible extracellular matrix that retains 300+ regulatory proteins.

Amniotic Fluid Tissue: R3 Stem Cell

R3 Stem Cell is investigating an Amniotic Fluid Tissue therapy for tendinopathy. Amniotic stem cells are derived from amniotic fluid obtained during scheduled caesarean sections from consenting donors. Amniotic fluid surrounds the foetus during pregnancy, feeding it. Normally, this fluid is discarded, but it can be used for those in need with the amazing ingredients it contains. Researchers have discovered that the amniotic fluid has an extremely high concentration of regenerative cells, even more than bone marrow in adults. Stem cell therapy is a type of intervention therapy that introduces stem cells into damaged tissues to treat an injury or disease. The company is testing the application of amniotic fluid tissue product to treat pain for all types of musculoskeletal conditions like Tendinitis, Osteoarthritis. The drug is currently in Phase II/III clinical trial.

Tendinopathy Market Outlook

Tendinopathy describes a complex, multifaceted pathology of the tendon, characterized by pain, a decline in function, and reduced exercise tolerance. The most common overuse tendinopathies involve the rotator cuff tendon, medial and lateral elbow epicondyles, patellar tendon, gluteal tendons, and the Achilles tendon. The prominent histological and molecular features of tendinopathy include disorganization of collagen fibers, increased microvasculature and sensory nerve innervation, dysregulated extracellular matrix homeostasis, increased immune cells, and inflammatory mediators, and enhanced cellular apoptosis (Millar et al., 2021).

The goals of tendinopathy treatment are to relieve the pain and reduce inflammation. The self-care includes rest, ice, and over-the-counter (OTC) pain relievers. This method helps decrease inflammation and swelling and brings temporary pain relief. This type of conservative treatment is generally all that is necessary to recover from true tendonitis. Although tendinitis usually resolves in a few days to a few weeks, unfortunately, it may take from 2-6 months to heal from long-term tendinopathy. Many tendon injuries turn into chronic problems that gradually get worse because the athlete continues the activity despite the nagging pain (Quinn, 2020).

Pain relievers including aspirin, naproxen sodium (Aleve), or ibuprofen (Advil, Motrin IB, others) may relieve discomfort associated with tendinitis. Topical creams with anti-inflammatory medication - popular in Europe and becoming increasingly available in the United States - also may be effective in relieving pain without the potential side effects of taking anti-inflammatory medications by mouth. Corticosteroids may be injected around a tendon to relieve tendinitis; injections of cortisone - naturally occurring corticosteroids - reduce inflammation and can help ease the pain.

Platelet-rich plasma (PRP) is a well-known therapy for the treatment of tendinopathy. It involves taking a blood sample and spinning the blood to separate the platelets and other healing factors. The solution is then injected into the area of chronic tendon irritation. Physical therapy is also beneficial and includes specific exercises designed to stretch and strengthen the affected muscle-tendon unit.

In situations where physical therapy has not resolved symptoms, surgical methods are recommended, including dry needling, which involves making small holes in the tendon with a fine needle to stimulate factors involved in tendon healing. Positive effects of the ultrasonic treatment on tendon healing have been observed, supported by solid evidence. It uses a small incision to insert a special device that removes tendon scar tissue with ultrasonic sound waves. Surgical repair may be needed, especially if the tendon has torn away from the bone (Mayo Clinic, n.d.). If tendinitis persists and there are calcium deposits around the tendon, extracorporeal shock wave therapy (ESWT) may help. In this method, a shock wave is passed through the skin, breaking up the calcium deposits. The deposits may also be removed surgically.

Key Findings
  • The market size of Tendinopathy in the 7MM is expected to increase in 2030 from USD 10,556 million in 2020 for the study period (2018-2030).
  • The current treatment regimen for the management of tendinopathy includes rest, ice, and over-the-counter (OTC) pain relievers. As per PMR, certain medications including over-the-counter non-steroidal anti-inflammatory medications, such as ibuprofen and naproxen are recommended for managing the condition.
  • Out of the current treatment market, the majority of the market size was generated by Surgery + NSAIDs, i.e., USD 6,252 million in 2020 in the 7MM. With the expected approval of Micronized DHACM and Amniotic Fluid Tissue, the market size of Surgery + NSAIDs is expected to decrease in 2030.
  • The market size for tendinopathy was found to be USD 6,315 million in 2020, in the US.
Studies suggest little or no inflammation is present in these conditions. Thus, traditional treatment modalities aimed at controlling inflammation such as corticosteroid injections and nonsteroidal anti-inflammatory medications (NSAIDs) may not be the most effective options. Platelet-Rich Plasma (PRP) is another technique that has been widely used in orthopaedic surgery and sports medicine to treat tendon injuries. However, the efficacy of PRP treatment for tendinopathy is controversial. The main advantages of PRP that enable its widespread use are its safety and simple preparation and administration methods. Hence the current market of tendinopathy is totally dependent on these therapies.

The United States Market Outlook

This section provides the total Tendinopathy market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total Tendinopathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Tendinopathy market size and market size by therapies in Japan are provided.

Tendinopathy Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Tendinopathy market or expected to get launched in the market during the study period 2018-2030. The analysis covers the Tendinopathy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Tendinopathy Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Tendinopathy emerging therapies.

Reimbursement Scenario in Tendinopathy
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the Tendinopathy market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Tendinopathy, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into Tendinopathy epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Tendinopathy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Tendinopathy market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Tendinopathy market.
Report Highlights
  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the Tendinopathy market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Tendinopathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Tendinopathy. The launch of emerging therapies will significantly impact the Tendinopathy market.
  • The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Tendinopathy Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Tendinopathy Pipeline Analysis
  • Tendinopathy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Tendinopathy Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Tendinopathy Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Tendinopathy Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis
Key Questions Answered

Market Insights:
  • What was the Tendinopathy market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Tendinopathy total market size as well as market size by therapies across the 7MM during the forecast period (2021-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Tendinopathy market size during the forecast period (2021-2030)?
  • At what CAGR, the Tendinopathy market is expected to grow at the 7MM level during the forecast period (2021-2030)?
  • What would be the Tendinopathy market outlook across the 7MM during the forecast period (2021-2030)?
  • What would be the Tendinopathy market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burdens, and unmet needs of Tendinopathy?
  • What is the historical Tendinopathy patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Tendinopathy at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Tendinopathy?
  • Out of the above-mentioned countries, which country would have the highest incident population of Tendinopathy during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Tendinopathy along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Tendinopathy in the US and Europe?
  • What are the Tendinopathy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Tendinopathy?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Tendinopathy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tendinopathy therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Tendinopathy and their status?
  • What are the key designations that have been granted for the emerging therapies for Tendinopathy?
  • What are the 7MM historical and forecasted market of Tendinopathy?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving Tendinopathy.
  • To understand the future market competition in the Tendinopathy market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Tendinopathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Tendinopathy market.
  • To understand the future market competition in the Tendinopathy market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ipsen
  • MiMedx Group
  • Novartis Pharmaceuticals
  • Orthocell Limited
  • R3 Stem Cell
  • MORE
1 Key Insights

2 Report Introduction

3 Tendinopathy Market Overview at a Glance
3.1 Market Share (%) Distribution of Tendinopathy in 2018
3.2 Market Share (%) Distribution of Tendinopathy in 2030

4 Executive Summary of Tendinopathy

5 Disease Background and Overview
5.1 Introduction
5.2 Classification
5.3 Causes
5.4 Signs and Symptoms
5.5 Risk factors
5.5.1 Sports
5.5.2 Occupation
5.5.3 Genetic factors
5.6 Histopathological changes
5.7 Pathophysiology
5.7.1 Mechanical Theory
5.7.2 Inflammation Theory
5.7.3 Apoptosis Theory
5.7.4 Vascular or neurogenic theory
5.7.5 Continuum model
5.8 Molecular Mechanism
5.9 Biomarkers
5.1 Diagnosis
5.10.1 Screening
5.10.2 Victorian Insitute of Sports Assessment (VISA)
5.11 Differential Diagnosis
5.12 Diagnostic Guidelines
5.13 Treatment
5.13.1 Rehabilitative exercise
5.13.2 NSAIDs, corticosteroids, and topical nitroglycerin
5.13.3 Cryotherapy
5.13.4 Extracorporeal shock wave therapy
5.13.5 Surgery
5.13.6 Recommendations for the treatment of tendinopathy
5.13.6.1 American Academy of Family Physician (AAFP)
5.13.6.2 The Ohio State University and Wexner Medical Center
5.14 Management

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Epidemiology Methodology
6.3 Total Incident Cases of Tendinopathy in the 7MM
6.4 Epidemiology of Tendinopathy
6.5 The United States
6.5.1 Total Incident Cases of Tendinopathy in the United States
6.5.2 Gender-specific Incident Cases of Tendinopathy in the United States
6.5.3 Type-specific Incident Cases of Tendinopathy in the United States
6.5.4 Region-specific Incident Cases of Tendinopathy in the United States
6.6 EU5
6.6.1 Germany
6.6.1.1 Total Incident Cases of Tendinopathy in Germany
6.6.1.2 Gender-specific Incidence of Tendinopathy in Germany
6.6.1.3 Type-specific Incident Cases of Tendinopathy in Germany
6.6.1.4 Region-Specific Incident Cases of Tendinopathy in Germany
6.6.2 France
6.6.2.1 Total Incident Cases of Tendinopathy in France
6.6.2.2 Gender-specific Incident Cases of Tendinopathy in France
6.6.2.3 Type-specific Incident Cases of Tendinopathy in France
6.6.2.4 Region-specific Incident Cases of Tendinopathy in France
6.6.3 Italy
6.6.3.1 Total Incident Cases of Tendinopathy in Italy
6.6.3.2 Gender-specific Incident Cases of Tendinopathy in Italy
6.6.3.3 Type-specific Incident Cases of Tendinopathy in Italy
6.6.3.4 Region-specific Incident of Tendinopathy in Italy
6.6.4 Spain
6.6.4.1 Total Incident Cases of Tendinopathy in Spain
6.6.4.2 Gender-specific Incident Cases of Tendinopathy in Spain
6.6.4.3 Type-specific Incident Cases of Tendinopathy in Spain
6.6.4.4 Region-specific Incident Cases of Tendinopathy in Spain
6.6.5 United Kingdom
6.6.5.1 Total Incident Cases of Tendinopathy in the United Kingdom
6.6.5.2 Gender-specific Incident Cases of Tendinopathy in the United Kingdom
6.6.5.3 Type-specific Incident Population of Tendinopathy in the United Kingdom
6.6.5.4 Region-specific Incident Cases of Tendinopathy in the United Kingdom
6.7 Japan
6.7.1 Total Incident Cases of Tendinopathy in Japan
6.7.2 Gender-specific Incident Cases of Tendinopathy in Japan
6.7.3 Type-specific Incident Cases of Tendinopathy in Japan
6.7.4 Region-specific Incident Cases of Tendinopathy in Japan

7 Organizations contributing towards Tendinopathy

8 Patient Journey

9 Case Reports
9.1 Achilles Tendinitis: A Case Report (US)
9.2 Achilles Tendinopathy: A case report (UK)
9.3 Acute Calcific Tendinitis of the Rectus Femoris: A case report

10 Emerging Therapies
10.1 Key Cross
10.2 Micronized DHACM (AmnioFix): MiMedx Group
10.2.1 Drug Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.4 Clinical Trials Information
10.2.5 Safety and Efficacy
10.2.6 Product Profile
10.3 Amniotic Fluid Tissue: R3 Stem Cell
10.3.1 Drug Description
10.3.2 Clinical Development
10.3.3 Clinical Trials Information
10.3.4 Product Profile
10.4 Secukinumab (AIN457): Novartis Pharmaceuticals
10.4.1 Drug Description
10.4.2 Clinical Development
10.4.3 Clinical Trials Information
10.4.4 Product Profile
10.5 Platelet-rich Plasma: University of Wisconsin-Madison/General Electric
10.5.1 Drug Description
10.5.2 Other Developmental Activities
10.5.3 Clinical Development
10.5.4 Clinical Trials Information
10.5.5 Product Profile
10.6 Botulinum toxin A (Dysport 500 Unit Powder): Ipsen
10.6.1 Drug Description
10.6.2 Clinical Development
10.6.3 Clinical Trials Information
10.6.4 Product Profile
10.7 Ortho-ATI: Orthocell Limited
10.7.1 Drug Description
10.7.2 Other Developmental Activities
10.7.3 Clinical Development
10.7.4 Safety and Efficacy
10.7.5 Product Profile

11 Tendinopathy: Seven Major Market Analysis
11.1 Key Findings
11.2 Market Methodology
11.3 Market Size of Tendinopathy in the 7MM in USD Million (2018-2030)
11.4 Market Size of Tendinopathy by Therapies in the 7MM
11.5 Market Outlook
11.6 Key Market Forecast Assumptions
11.7 United States Market Size
11.7.1 Total Market Size of Tendinopathy in the United States
11.7.2 Market Size of Tendinopathy by Therapies in the United States
11.8 EU-5 Market Size
11.8.1 Germany
11.8.1.1 Total Market size of Tendinopathy in Germany
11.8.1.2 Market Size of Tendinopathy by Therapies in Germany
11.8.2 France
11.8.2.1 Total Market size of Tendinopathy in France
11.8.2.2 Market Size of Tendinopathy by Therapies in France
11.8.3 Italy
11.8.3.1 Total Market size of Tendinopathy in Italy
11.8.3.2 Market Size of Tendinopathy by Therapies in Italy
11.8.4 Spain
11.8.4.1 Total Market size of Tendinopathy in Spain
11.8.4.2 Market Size of Tendinopathy by Therapies in Spain
11.8.5 United Kingdom
11.8.5.1 Total Market size of Tendinopathy in the United Kingdom
11.8.5.2 Market Size of Tendinopathy by Therapies in the United Kingdom
11.9 Japan
11.9.1 Total Market size of Tendinopathy in Japan
11.9.2 Market Size of Tendinopathy by Therapies in Japan

12 KOL Views

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Unmet Needs

17 Appendix
17.1 Bibliography
17.2 Report Methodology

18 Publisher Capabilities

19 Disclaimer

20 About the Publisher

List of Tables
Table 1: Summary of Tendinopathy Market, Epidemiology, and Key Events (2018-2030)
Table 2: Common sites of overuse tendon injuries
Table 3: Histopathological classification of tendon disorders
Table 4: Comparison of the normal and tendinopathic tendon by macroscopic, light, and electron microscopic and ultrasound findings
Table 5: Tests to aid in the diagnosis of tendinopathy
Table 6: Differential diagnosis of tendinopathy
Table 7: Recommendations for managing tendinopathy
Table 8: Treatment for Chronic Tendon Injuries
Table 9: Key Recommendations for practice
Table 10: Recommendations for the treatment of tendinopathy
Table 11: Pain Reduction and Load Management
Table 12: Isotonic Loading Progression
Table 13: Energy Storage Loading Progression (Plyometrics)
Table 14: Return to Sport/Activity
Table 15: Total Incident Cases of Tendinopathy in the 7MM, in Thousand (2018-2030)
Table 16: Total Incident Cases of Tendinopathy in the United States, in Thousand (2018-2030)
Table 17: Gender-specific Incident Cases of Tendinopathy in the US, in Thousand (2018-2030)
Table 18: Type-specific Incident Cases of Tendinopathy in the US, in Thousand (2018-2030)
Table 19: Region-specific Incident Cases of Tendinopathy in the United States, in Thousand (2018-2030)
Table 20: Total Incident Cases of Tendinopathy in Germany, in Thousands (2018-2030)
Table 21: Gender-specific Incident Cases of Tendinopathy in Germany, in Thousand (2018-2030)
Table 22: Type-specific Incident Cases of Tendinopathy in Germany, in Thousand (2018-2030)
Table 23: Region-specific Incident Cases of Tendinopathy in Germany, in Thousand (2018-2030)
Table 24: Total Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Table 25: Gender-specific Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Table 26: Type-specific Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Table 27: Region-specific Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Table 28: Total Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Table 29: Gender-specific Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Table 30: Type-specific Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Table 31: Region-specific Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Table 32: Total Incident Cases of Tendinopathy in Spain, in Thousand (2018-2030)
Table 33: Gender-specific Incident Cases of Tendinopathy in Spain, in Thousand (2018-2030)
Table 34: Type-specific Incident Cases of Tendinopathy in Spain, in Thousand (2018-2030)
Table 35: Region-specific Incident Cases of tendinopathy in Spain, in Thousand (2018-2030)
Table 36: Total Incident Cases of Tendinopathy in the UK, in Thousand (2018-2030)
Table 37: Gender-specific Incident Cases of Tendinopathy in the UK, in Thousand (2018-2030)
Table 38: Type-specific Incident Cases of Tendinopathy in the UK, in Thousand (2018-2030)
Table 39: Region-specific Incident Cases of Tendinopathy in the UK, in Thousand (2018-2030)
Table 40: Total Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Table 41: Gender-specific Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Table 42: Type-specific Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Table 43: Region-specific Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Table 44: Organizations contributing toward Tendinopathy
Table 45: Comparison of emerging drugs under development
Table 46: Micronized DHACM, Clinical Trial Description, 2021
Table 47: Amniotic Fluid Tissue, Clinical Trial Description, 2021
Table 48: Secukinumab, Clinical Trial Description, 2021
Table 49: Platelet-Rich Plasma Therapy, Clinical Trial Description, 2021
Table 50: Dysport 500 Unit, Clinical Trial Description, 2021
Table 51: Market Size of Tendinopathy in the 7MM in USD Million (2018-2030)
Table 52: Market Size of Tendinopathy by therapies in the 7MM, in USD Million (2018-2030)
Table 53: Key Market Forecast Assumptions for Micronized DHACM
Table 54: Key Market Forecast Assumptions for Amniotic Fluid Tissue
Table 55: Market Size of Tendinopathy by therapies in the US, in USD Million (2018-2030)
Table 56: Germany Market Size of Tendinopathy in USD Million (2018-2030)
Table 57: Market Size of Tendinopathy by therapies in Germany, in USD Million (2018-2030)
Table 58: France Market Size of Tendinopathy in USD Million (2018-2030)
Table 59: Market Size of Tendinopathy by therapies in France, in USD Million (2018-2030)
Table 60: Italy Market Size of Tendinopathy in USD Million (2018-2030)
Table 61: Market Size of Tendinopathy by therapies in Italy, in USD Million (2018-2030)
Table 62: Spain Market Size of Tendinopathy in USD Million (2018-2030)
Table 63: Market Size of Tendinopathy by therapies in Spain, in USD Million (2018-2030)
Table 64: The UK Market Size of Tendinopathy in USD Million (2018-2030)
Table 65: Market Size of Tendinopathy by therapies in the UK, in USD Million (2018-2030)
Table 66: Japan Market Size of Tendinopathy in USD Million (2018-2030)
Table 67: Market Size of Tendinopathy by therapies in Japan, in USD Million (2018-2030)

List of Figures
Figure 1: Healthy Tendon vs. Tendon in Tendinopathy
Figure 2: Classification of Tendinopathy
Figure 3: Pathophysiology of tendinopathy
Figure 4: Molecular Mechanisms of Tendinopathy
Figure 5: Management of Tendinopathy
Figure 6: Total Incident Cases of Tendinopathy in the 7MM, in Thousand (2018-2030)
Figure 7: Total Incident Cases of Tendinopathy in the United States, in Thousand (2018-2030)
Figure 8: Gender-specific Incident Cases of Tendinopathy in the US, in Thousand (2018-2030)
Figure 9: Type-specific Incident Cases of Tendinopathy in the US, in Thousand (2018-2030)
Figure 10: Region-specific Incident Cases of Tendinopathy in the United States, in Thousand (2018-2030)
Figure 11: Total Incident Cases of Tendinopathy in Germany, in Thousands (2018-2030)
Figure 12: Gender-specific Incident Cases of Tendinopathy in Germany, in Thousand (2018-2030)
Figure 13: Type-specific Incident Cases of Tendinopathy in Germany, in Thousand (2018-2030)
Figure 14: Region-specific Incident Cases Tendinopathy in Germany, in Thousand (2018-2030)
Figure 15: Total Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Figure 16: Gender-specific Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Figure 17: Type-specific Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Figure 18: Region-specific Incident Cases of Tendinopathy in France, in Thousand (2018-2030)
Figure 19: Total Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Figure 20: Gender-specific Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Figure 21: Type-specific Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Figure 22: Region-specific Incident Cases of Tendinopathy in Italy, in Thousand (2018-2030)
Figure 23: Total Incident Cases of Tendinopathy in Spain, in Thousand (2018-2030)
Figure 24: Gender-specific Incident Cases of Tendinopathy in Spain, in Thousand (2018-2030)
Figure 25: Type-specific Incident Cases of Tendinopathy in Spain, in Thousand (2018-2030)
Figure 26: Region-specific Incident Cases of tendinopathy in Spain, in Thousand (2018-2030)
Figure 27: Total Incident Cases of Tendinopathy in the UK, in Thousand (2018-2030)
Figure 28: Gender-specific Incident Cases of Tendinopathy in the UK, in Thousand (2018-2030)
Figure 29: Type-specific Incident Population of Tendinopathy in the UK, in Thousand (2018-2030)
Figure 30: Region-specific Incident Cases of Tendinopathy in the UK, in Thousand (2018-2030)
Figure 31: Total Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Figure 32: Gender-specific Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Figure 33: Type-specific Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Figure 34: Region-specific Incident Cases of Tendinopathy in Japan, in Thousand (2018-2030)
Figure 35: Market Size of Tendinopathy in the 7MM in USD Million (2018-2030)
Figure 36: Seven Major Market Size of Tendinopathy by Therapies in the 7MM, in USD Million (2018-2030)
Figure 37: Market Size of Tendinopathy in the US, USD Millions (2018-2030)
Figure 38: Market Size of Tendinopathy in the US, USD Millions (2018-2030)
Figure 39: Market Size of Tendinopathy by therapies in the United States, in USD Million (2018-2030)
Figure 40: Market Size of Tendinopathy in Germany, USD Million (2018-2030)
Figure 41: Germany Market Size of Tendinopathy by Therapies in USD Million (2018-2030)
Figure 42: Market Size of Tendinopathy in France, USD Million (2018-2030)
Figure 43: France Market Size of Tendinopathy by Therapies in USD Million (2018-2030)
Figure 44: Market Size of Tendinopathy in Italy, USD Million (2018-2030)
Figure 45: Italy Market Size of Tendinopathy by Therapies in USD Million (2018-2030)
Figure 46: Market Size of Tendinopathy in Spain, USD Million (2018-2030)
Figure 47: Market Size of Tendinopathy by therapies in Spain in USD Million (2018-2030)
Figure 48: Market Size of Tendinopathy in the United Kingdom, USD Million (2018-2030)
Figure 49: UK Market Size of Tendinopathy by Therapies in USD Million (2018-2030)
Figure 50: Market Size of Tendinopathy in Japan, USD Million (2018-2030)
Figure 51: Japan Market Size of Tendinopathy by Therapies in USD Million (2018-2030)
Figure 52: Market Drivers
Figure 53: Market Barriers
Figure 54: Unmet Needs
Note: Product cover images may vary from those shown
  • MiMedx Group
  • R3 Stem Cell
  • Novartis Pharmaceuticals
  • University of Wisconsin-Madison/General Electric
  • Ipsen
  • Orthocell Limited
Note: Product cover images may vary from those shown
Adroll
adroll